Transforming Growth Factor Beta Signaling in Growth of Estrogen-Insensitive Metastatic Bone Lesions
Abstract
While many women with breast cancer will use estrogen receptor therapeutics such as fulvestrant, resistance is nearly inevitable. Recently, it has been noted that the epidermal growth factor receptor (EGFR) family plays a vital role in metastasis to bone; also cross signaling with the transforming growth factor receptor type II (TGFBR2) has been noted to increase levels of destructive environmental cytokines. Therefore we are examining the role of EGFR/TGFBR2 cross talk in bone metastatic breast cancer. The study of these pathways are important to metastatic breast cancer, as they have been known to increase levels of the destructive cytokine parathyroid hormone related protein (PTHrP), which causes increased osteolysis within the bone environment. To elucidate the connection between these two vital receptors may led to further progression in therapeutics for those women with EGFR positive tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2012
- Accession Number
- ADA558405
Entities
People
- Nicole Nickerson
Organizations
- Indiana University